Ehud N Arbit

Author:

Ehud Arbit

ISBN #:

0879935529

US Patent:

7384914, Jun 10, 2008

Filed:

Jan 6, 2004

Appl. No.:

10/541433

Inventors:

Michael Goldberg - Tarrytown NY, US
Ehud Arbit - Tarrytown NY, US

Assignee:

Emisphere Technologies, Inc. - Cedar Knolls NJ

International Classification:

A61K 38/28

US Classification:

514 3, 530303, 424434, 424439, 424464, 424489

Abstract:

A method for protection of a mammal that has impaired glucose tolerance or early stage diabetes mellitus from developing overt or insulin dependent diabetes comprises administering an orally effective dose of a pharmaceutical formulation comprising insulin at nighttime, e. g. , at or shortly before bedtime.

US Patent:

7429564, Sep 30, 2008

Filed:

Jan 7, 2003

Appl. No.:

10/500822

Inventors:

Ehud Arbit - Tarrytown NY, US
Richat Abbas - Audubon PA, US
Michael Goldberg - Tarrytown NY, US
T. Cooper Woods - New York NY, US
Steven Dinh - Tarrytown NY, US
Vivien Wong - Scarsdale NY, US

Assignee:

Emisphere Technologies, Inc. - Cedar Knolls NJ

International Classification:

A61K 38/28

US Classification:

514 4

Abstract:

Pharmaceutical dosage forms for oral administration to a patient for the treatment of diabetes, comprising insulin and a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and that result in a lower incidence of vascular diseases associated with the repeated administration of insulin are disclosed. Also disclosed is a method of attenuating the undesirable incidence of diseases associated with chronic dosing of insulin is provided whereby the oral administration to a patient of insulin along with a suitable delivery agent that facilitates the absorption of insulin from the gastrointestinal tract of the patient in a therapeutically effective amount, for treatment of diabetes.

US Patent:

8324156, Dec 4, 2012

Filed:

Aug 24, 2009

Appl. No.:

12/546283

Inventors:

Ehud Arbit - Tarrytown NY, US
Michael Goldberg - Tarrytown NY, US

Assignee:

Emisphere Technologies, Inc. - Cedar Knolls NJ

International Classification:

A61K 38/28

US Classification:

514 59

Abstract:

Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e. g. , within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy.

US Patent:

8513300, Aug 20, 2013

Filed:

Apr 16, 2008

Appl. No.:

12/103821

Inventors:

Richat Abbas - Mohegan Lake NY, US
Ehud Arbit - Tarrytown NY, US
Michael Goldberg - Tarrytown NY, US
Vivien Wong - Tarrytown NY, US
Donald J. Sarubbi - Bolton MA, US

Assignee:

Emisphere Technologies, Inc. - Roseland NJ

International Classification:

A01N 43/16
A61K 31/35

US Classification:

514451, 514183, 514449, 424400

Abstract:

An oral dosage form comprises cromolyn sodium (sodium or disodium cromoglycate), and an acylated amino acid delivery agent.

US Patent:

8597199, Dec 3, 2013

Filed:

Oct 11, 2010

Appl. No.:

12/902030

Inventors:

Ziv Harish - Tenafly NJ, US
Isaac Rubinstein - Haworth NJ, US
Ehud Arbit - Englewood NJ, US
Russ Weinzimmer - Milford NH, US

International Classification:

A61B 5/00

US Classification:

600556

Abstract:

An allergy skin test device is disclosed that causes less pain than commonly used devices that include multi-point sharp puncture heads. The allergy skin test device incorporates multiple dull pressure heads distributed amongst the sharp multi-point sharp puncture heads, each dull pressure head activating a neurological pain gate that reduces pain sensation typically caused by the neighboring multi-point head when it engages the skin.

US Patent:

20040259952, Dec 23, 2004

Filed:

May 28, 2004

Appl. No.:

10/497286

Inventors:

Richat Abbas - Mohegan Lake NY, US
Ehud Arbit - Tarrytown NY, US
Michael Goldberg - Tarrytown NY, US
Vivien Wong - Tarrytown NY, US
Donald Sarubbi - Carmel NY, US

International Classification:

A61K031/19

US Classification:

514/571000

Abstract:

An oral dosage form comprises cromolyn sodium (sodium or disodium cromoglycate), and an acylated amino acid delivery agent.

US Patent:

20050203001, Sep 15, 2005

Filed:

Mar 4, 2005

Appl. No.:

11/072941

Inventors:

Ehud Arbit - Tarrytown NY, US
Michael Goldberg - Tarrytown NY, US
Shingai Majuru - Tarrytown NY, US

Assignee:

Emisphere Technologies, Inc. - Tarrytown NY

International Classification:

A61K038/28

US Classification:

514003000

Abstract:

Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy.

US Patent:

20060078622, Apr 13, 2006

Filed:

Aug 15, 2005

Appl. No.:

11/204756

Inventors:

Shingai Majuru - Brewster NY, US
Puchun Liu - Somers NY, US
Steve Dinh - Briarcliff Manor NY, US
Jun Liao - Yorktown Heights NY, US
Jongbin Lee - New City NY, US
Ehud Arbit - Englewood NJ, US
Nikhil Dhoot - Wappingers Falls NY, US
Halina Levchik - Croton on Hudson NY, US
George Klcin - Tarrytown NY, US
Jamila Harris - Flushing NY, US
Nai Wang - Long Island City NY, US

Assignee:

Emisphere Technologies, Inc. - Tarrytown NY

International Classification:

A61K 9/14

US Classification:

424489000

Abstract:

This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent.